HHS-2026-ACL-CIP-AAFP-0017: A Demonstration to Scale Innovative Person-Centered Approaches to Falls Prevention through Clinical-Community Partnerships
Closed
This grant is closed. A newer notice from the same program is forecast: National Center for Law and Elder Rights (HHS-2027-ACL-AOA-LMRC-0019). Status: Expected deadline March 5, 2027. It is in our archive of Administration for Community Living notices from 2026.
Administration for Community Living offered grants of up to $4.7 million (at least $4.7 million) to nonprofits, colleges and universities, state and local governments and tribes. It expected to make one award worth $4.7 million in total. Applications closed on July 27, 2026.
From the official notice on Grants.gov, last changed June 26, 2026. Checked November 7, 2026.
- Award ceiling$4.7 million
- Award floor$4.7 million
- Total funding$4.7 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | June 26, 2026 |
|---|---|
| Deadline | July 27, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments and tribes.
All 11 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
Foreign entities are not eligible to compete for, or receive, awards made under this announcement. Faith-based and community organizations that meet the eligibility requirements are eligible to receive awards under this funding opportunity announcement.
Is this a realistic fit?
- Past Special Programs for the Aging, Title IV, and Title II, Discretionary Projects awards averaged $1.3 million; this notice allows up to $4.7 million per award.
- Most of the program's money (70% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The purpose of this funding announcement is to demonstrate and evaluate the scalability of person-centered and evidence-based approaches to falls prevention that leverage clinical and community partnerships and related data and technology tools. ACL intends to award a single cooperative agreement to one grantee for a three-year project period with the expectation that the grantee will fund up to three demonstrations. This award will build on the ACL Innovation Lab to demonstrate the scaling of person-centered and evidence-based approaches to falls prevention and related chronic disease management programs through community care hubs and their respective clinical partners and community-based organizations in the aging services network. The successful applicant will be expected to collaborate with ACL in the design and implementation of these demonstrations in the scalability of falls prevention and related chronic disease management interventions through approximately three advanced community care hubs that support care transitions and screening for the risk of falls. They should also have the capacity to 1) do rapid cycle evaluation to iterate and improve the impact of the interventions as they are scaled and, 2) administer sub-awards to community care hubs that can implement and scale person-centered interventions enabled by artificial intelligence, data analytics, assistive technology, virtual delivery of interventions, tools to support consumer behaviors, and related data infrastructure.
Who has won Special Programs for the Aging, Title IV, and Title II, Discretionary Projects grants before
From fiscal 2021 to 2025, Special Programs for the Aging, Title IV, and Title II, Discretionary Projects (93.048) awarded $502 million across 382 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Usaging | District of Columbia | 8 | $105 million |
| National Council on the Aging, Inc. | Virginia | 7 | $71.8 million |
| The Jewish Federations of North America, Inc. | New York | 2 | $36.1 million |
| Oasis Institute | Missouri | 3 | $23.9 million |
| Generations United Inc | District of Columbia | 1 | $9.9 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HHS-2027-ACL-AOA-LMRC-0019, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HHS-2026-ACL-CIP-AAFP-0017 still open?
No. It closed on July 27, 2026. A newer notice is forecast: HHS-2027-ACL-AOA-LMRC-0019, expected deadline March 5, 2027.
Who can apply for A Demonstration to Scale Innovative Person-Centered Approaches to Falls Prevention through Clinical-Community Partnerships?
Administration for Community Living accepted applications from nonprofits, colleges and universities, state and local governments and tribes. The notice adds further conditions, so read its eligibility section.
What is the deadline for A Demonstration to Scale Innovative Person-Centered Approaches to Falls Prevention through Clinical-Community Partnerships?
Closed July 27, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $4.7 million each. About $4.7 million in total for one award.
Who has won Special Programs for the Aging, Title IV, and Title II, Discretionary Projects grants before?
The largest recipients over five fiscal years were Usaging, National Council on the Aging, Inc., The Jewish Federations of North America, Inc. The program made 382 awards worth $502 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)